Health:
In clinical studies over the past 20 years, our licensed Immunitor oral pill immunotherapeutics have consistently proven the science and demonstrated superior safety and efficacy in diseases such as late-stage cancers, tuberculosis, HIV/AIDS, hepatitis.In many cases where other treatments have failed.
Key Capital is now working with Immunitor towards product registrations and commercializations that will contribute to a better healthcare future.
NEW YORK, NY, April 29, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises it is evident the COVID situation in India is a humanitarian catastrophe, and that although the head of WHO states it is “beyond heartbreaking”, it appears that the COVID crisis in India will unfortunately get a lot worse.
NEW YORK, NY, April 26, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that Immunitor, its Licensing partner, continues to receive favorable reports from people in Asian and African countries using the Immunitor HAP-V+ Immune Supplement in cases of respiratory infections.
NEW YORK, NY, April 8, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that in association with its partner, global oral pill vaccine pioneer Immunitor (Thailand) Co., Ltd, the Company is today launching its unique M.vaccae and magnesium dietary supplement in the $18 billion Anxiety and Stress market.
